Regulatory News :
ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces its financial calendar for 2014.
January 27, 2014: | Publication of Q4 and full year 2013 revenues (after market) | |
April 29, 2014: | Publication of 2013 annual results (after market) | |
May 15, 2014: | Publication of Q1 2014 revenues (after market) | |
June 17, 2014: | Annual shareholders' meeting | |
July 16, 2014: | Publication of Q2 2014 revenues (after market) | |
September 2, 2014: | Publication of H1 2014 results (after market) | |
November 4, 2014: | Publication of Q3 2014 revenues (after market) |
Beyond these periodicals, investors are invited to consult the website of the company (www.erytech.com) where information is regularly updated. All corporate and financial information on the company is available on the company's website, in the Investors' section.
About ERYTECH and GRASPA®: www.erytech.com
Founded in Lyon in 2004, ERYTECH is a French biopharmaceutical company
providing new prospects for cancer patients, particularly those with
acute leukemia and selected solid tumors.
Every year about 50,000
patients are diagnosed with Acute Lymphoblastic Leukemia (ALL) or Acute
Myeloid Leukemia (AML), the two forms of acute leukemia. Today, for
about 80% of these patients, mainly adults and relapsing patients, there
is no adequate solution due to the toxicity of existing treatments. By
encapsulating the asparaginase enzyme in red blood cells, ERYTECH has
developed GRASPA®, an original and effective treatment that targets
leukemia cells through "starvation" while significantly reducing the
side effects for patients, and allowing all patients to be treated, even
the most fragile ones, representing a market opportunity of more than
EUR 1 billion. GRASPA® is currently completing Phase III clinical
development in Acute Lymphoblastic Leukemia (ALL) and is in Phase IIb
clinical trial in Acute Myeloid Leukemia (AML) in Europe. The product
received FDA clearance to start clinical development in ALL in the USA.
ERYTECH has concluded distribution partnership agreements for Europe
with Orphan Europe (Recordati Group), and with TEVA for Israel. The
company is also developing other indications in solid tumors and certain
orphan indications outside oncology. ERYTECH has its own GMP-approved
and operational manufacturing site.
ERYTECH is listed on Euronext regulated market in Paris. (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharm. & Bio and Next Biotech indexes.
ERYTECH
Gil Beyen
Chairman and CEO
or
Pierre-Olivier
Goineau
Vice President and COO
Tel: +33 4 78 74 44
38
investors@erytech.com
or
NewCap.
Julien
Perez / Emmanuel Huynh, Tel: +33 1 44 71 98 52
Investor and
press relations
erytech@newcap.fr